All of the following are true about staing betablocker therapy in cases of CHF, Except
**Core Concept**
Beta blockers are a cornerstone in the management of chronic heart failure (CHF), despite their negative inotropic effects. They work by reducing the sympathetic nervous system's influence on the heart, thereby decreasing heart rate, contractility, and cardiac output. This leads to a reduction in myocardial oxygen demand and a decrease in the heart's workload.
**Why the Correct Answer is Right**
Beta blockers, such as carvedilol and metoprolol succinate, are initiated at low doses in patients with CHF to avoid exacerbating the condition. The mechanism involves the blockade of beta-1 receptors, which are responsible for increasing heart rate and contractility. By reducing these effects, beta blockers help to decrease the heart's workload and improve symptoms. Additionally, beta blockers have been shown to decrease mortality and hospitalization rates in patients with CHF.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because beta blockers are not contraindicated in CHF, as previously thought. In fact, they are a recommended treatment for patients with heart failure with reduced ejection fraction (HFrEF).
**Option B:** This option is incorrect because beta blockers do not directly increase cardiac output. Instead, they reduce the heart's workload, which can lead to an improvement in cardiac function over time.
**Option C:** This option is incorrect because beta blockers are not contraindicated in patients with asthma, unless they have a history of severe bronchospasm. However, this is not a contraindication for beta blockers in CHF.
**Clinical Pearl / High-Yield Fact**
The "START-EXT" trial demonstrated that extended-release metoprolol succinate reduced the risk of hospitalization and mortality in patients with CHF, even in those with a history of asthma.
**Correct Answer: A. Beta blockers are contraindicated in CHF.**